WebDoctor Encyclopedia

Childhood Chronic myeloid & MDS

Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is a rare disease in which abnormal immune cells build up in bones, skin and other organs. It is most common in young children and is usually curable.

Medically reviewed Last reviewed October 21, 2026

What is Langerhans cell histiocytosis?

Langerhans cell histiocytosis (LCH) is a rare disease in which abnormal immune cells, called LCH cells, build up in one or more parts of the body and form lesions. These cells look like Langerhans cells, the immune cells normally found in the skin, but they actually come from the bone marrow.

LCH can affect almost any organ. The bones are involved most often, followed by the skin, the pituitary gland, the lungs, the liver, the spleen, the bone marrow and the lymph nodes. Some people have a single bone lesion that heals on its own, while others have widespread disease that needs months of treatment.

For many years LCH was thought to be an immune disorder. Since 2010 it has been known that most cases are driven by gene mutations in the MAPK pathway, especially BRAF V600E. The WHO Classification of Haematolymphoid Tumours, 5th edition (2022) therefore lists LCH as a histiocytic and dendritic cell neoplasm, and it is treated by cancer specialists. Many experts describe it as an “inflammatory myeloid neoplasia”, because it has features of both cancer and inflammation.

Older names for LCH include histiocytosis X, eosinophilic granuloma (a single bone lesion), Hand-Schuller-Christian disease and Letterer-Siwe disease. These names are no longer used for diagnosis.

1. How common is it?

Feature Details
Children About 4-5 per million under the age of 15 each year; the most common histiocytic disease
Peak age 1-3 years; can occur at any age, including newborns
Adults About 1-2 per million each year; often underdiagnosed
Sex Slightly more common in boys and men
Adults who smoke Pulmonary LCH (lung-only) occurs almost only in current or former smokers, usually aged 20-40

LCH is not infectious and cannot be passed on to other people. It is almost never inherited.

2. Causes

LCH is caused by gene changes that arise in immature myeloid cells, the bone marrow cells that develop into immune cells. These changes switch on the MAPK/ERK signalling pathway, which makes the cells grow, survive and gather in tissues together with other inflammatory cells.

Gene change How often Notes
BRAF V600E About 50-60% Linked with more extensive disease and higher risk of reactivation in children; can be targeted with BRAF inhibitors
MAP2K1 (MEK1) About 20-25% Usually found in tumours without BRAF V600E; can be targeted with MEK inhibitors
Other BRAF changes, ARAF, KRAS, NRAS Small numbers Also activate the MAPK pathway

The stage at which the mutation occurs seems to shape the disease. A mutation in an early bone marrow stem cell tends to cause widespread, high-risk disease, while a mutation in a more mature cell tends to cause a single lesion.

In adults with pulmonary LCH, tobacco smoke is the main trigger. No lifestyle cause is known for LCH in children.

3. Types of LCH

Doctors group LCH according to how many organ systems are involved and whether “risk organs” are affected. This grouping guides treatment, following the Histiocyte Society guidelines.

Group What it means Examples
Single-system, unifocal One lesion in one system A single skull or leg bone lesion; one skin patch
Single-system, multifocal Several lesions in one system Several bone lesions
Single-system, special sites One lesion in a “CNS-risk” bone or near the spine Lesions in the bones of the face, eye socket, ear or skull base; vertebral lesions with spread into the spinal canal
Pulmonary LCH Lung-only disease, mostly in adult smokers Nodules and cysts in the upper parts of both lungs
Multisystem, without risk organs Two or more systems, but not the liver, spleen or bone marrow Bone plus skin, or bone plus pituitary
Multisystem, with risk organs Involves the liver, spleen or bone marrow Usually infants with rash, enlarged liver and spleen, and low blood counts

“CNS-risk” lesions are bone lesions of the skull base, eye socket, ear (temporal bone and mastoid), sphenoid and other facial bones. They carry a higher risk of later diabetes insipidus and brain involvement, so treatment is usually recommended even if the lesion is single.

4. How does it look?

4.1 On the skin and in the mouth

Site Typical appearance
Scalp A scaly, greasy, crusting rash that looks like severe cradle cap or seborrhoeic dermatitis and does not respond to usual treatment
Skin folds and nappy area Red, raw, sometimes weeping areas behind the ears, in the armpits, groin and nappy area
Trunk Small reddish-brown or purple bumps (papules), sometimes with crusts or tiny bleeding spots (petechiae)
Newborns Scattered brown-red bumps or blisters at birth; sometimes clear up on their own, but need full assessment
Mouth and gums Swollen, sore gums; loose teeth; “floating teeth” on X-ray; ulcers
Ears Long-lasting discharge from the ear that does not settle with antibiotics

4.2 On scans and X-rays

Feature Typical appearance
Skull Sharp-edged, “punched-out” holes in the bone, sometimes with a “bevelled edge” or a small fragment of bone inside
Spine Vertebra plana: a vertebra collapsed into a thin flat disc
Long bones Lytic (bone-destroying) areas, sometimes with new bone along the surface
Jaw Bone loss around the teeth so they look as if they are “floating”
Lungs (adult smokers) On CT, small nodules and thin-walled, oddly shaped cysts, mainly in the upper and middle lung, sparing the lowest parts
Pituitary On MRI, a thickened pituitary stalk and loss of the normal bright spot of the back of the gland
PET-CT Shows active lesions throughout the body and how they respond to treatment

4.3 Under the microscope

LCH cells are medium-sized oval cells with a folded or grooved nucleus that looks like a coffee bean. They are mixed with eosinophils, lymphocytes, macrophages and giant cells. The diagnosis is confirmed when the cells stain positive for CD1a and CD207 (langerin). A stain or genetic test for BRAF V600E is usually done as well.

5. Symptoms

Symptoms depend on which parts of the body are affected. Many children have only a single painful bone lump, while others have several organs involved.

Organ Common symptoms
Bone (about 80% of children) Pain and a tender swelling, most often on the skull; limp or back pain; a fracture after minor injury; swelling around the eye if the eye socket is involved
Skin (about 30-40%) A rash that does not go away, especially on the scalp, in skin folds or the nappy area
Pituitary gland Diabetes insipidus: very heavy thirst and passing large amounts of pale urine, including bedwetting; later, poor growth or delayed puberty
Ear Ear discharge, recurrent ear infections, hearing loss
Mouth Sore swollen gums, loose or early loss of teeth
Lymph nodes Swollen glands in the neck or elsewhere
Liver and spleen Swollen tummy, jaundice, poor feeding, fluid in the abdomen
Bone marrow Paleness and tiredness (anaemia), bruising or bleeding (low platelets), frequent infections
Lungs Dry cough and breathlessness; in adult smokers, sometimes sudden chest pain and breathlessness from a collapsed lung (pneumothorax)
Brain Rarely, a mass in the brain; or, years later, neurodegenerative LCH with clumsiness, unsteady walking, slurred speech, and learning or behaviour problems
General Fever, weight loss, poor growth, irritability

When to see a doctor urgently

  • A baby with a persistent rash plus a swollen tummy, fever, poor feeding or pale skin.
  • A child who suddenly drinks and urinates much more than usual.
  • Sudden chest pain and breathlessness in a young adult who smokes.

6. Diagnosis

A biopsy of an affected area is needed to confirm LCH. After diagnosis, tests are done to find out how widespread the disease is.

Test Purpose
Biopsy (bone, skin, lymph node or other) Confirms LCH cells (CD1a and CD207 positive)
BRAF V600E and MAPK gene testing Guides targeted treatment if needed
Full blood count, liver tests, clotting tests Check the bone marrow and liver
Water deprivation test or urine and blood concentration tests Check for diabetes insipidus
Skeletal survey, whole-body MRI or PET-CT Look for other bone lesions and measure activity
Chest X-ray or CT Look for lung involvement
Brain and pituitary MRI For CNS-risk lesions, diabetes insipidus or nervous system symptoms
Ultrasound of the abdomen Check the liver and spleen
Hearing test, lung function test When the ear or lungs are involved

7. Treatment

Treatment depends on the extent of the disease and the age of the patient. Children are usually treated according to Histiocyte Society protocols, such as the international LCH-IV study. Adults follow international expert guidance published in 2022.

7.1 Treatment by type of LCH

Type Usual approach
Single skin lesion in an infant Often observation; some clear up on their own; skin creams in some cases
Single bone lesion (not CNS-risk) Biopsy and scraping (curettage) is often enough; sometimes a steroid injection into the lesion
CNS-risk bone lesion, several bone lesions, or multisystem disease Vinblastine and prednisone chemotherapy for 12 months
Multisystem disease with risk organs Vinblastine and prednisone, often with mercaptopurine; second-line chemotherapy or targeted drugs if response is poor
Pulmonary LCH in adults Stopping smoking completely; this alone often stabilises or improves the lungs. Medicines if disease progresses
Adult multisystem or bone disease Cytarabine or cladribine chemotherapy, or targeted drugs

7.2 Medicines used in LCH

Treatment How it works How it is given Benefit Main side effects
Vinblastine with prednisone Chemotherapy plus a steroid Weekly injection for 6-12 weeks, then every 3 weeks to complete 12 months; prednisone tablets Standard first-line treatment in children; 12 months lowers the risk of reactivation (LCH-III study) Low blood counts, constipation, nerve tingling; steroid effects such as mood changes and weight gain
Cytarabine Chemotherapy Injections in short courses every few weeks Effective first-line choice in adults and second-line in children Low blood counts, nausea
Cladribine Chemotherapy that targets immune cells Injections or drip for a few days each month Effective for relapsed disease and adults Low blood counts and infections
Clofarabine Chemotherapy Drip for 5 days each month Used for disease that has not responded to other treatment Low blood counts and infections
Dabrafenib, vemurafenib BRAF inhibitors Tablets or capsules High response rates in BRAF V600E disease, including infants with risk-organ disease Rash, fever, joint pain; disease often returns if stopped
Cobimetinib, trametinib MEK inhibitors Tablets Work whether or not BRAF is mutated; cobimetinib approved in the USA for histiocytic neoplasms in 2022 Rash, diarrhoea, eye and heart effects
Stem cell transplant Replaces the bone marrow Specialist centres only For rare cases resistant to all other treatment Serious infections and other complications

7.3 Other treatments

  • Desmopressin tablets, melts or spray replace the missing hormone in diabetes insipidus. This is usually lifelong.
  • Hormone replacement for other pituitary hormone deficiencies, such as growth hormone.
  • Surgery for a lesion threatening the spinal cord, or to stabilise a collapsed bone.
  • Radiotherapy at low dose is now rarely used, mainly in adults with a lesion that cannot be treated otherwise.
  • Lung transplant for adults with severe pulmonary LCH and lung failure.

8. Outlook

Most people with LCH survive. The outlook depends mainly on whether risk organs are involved and how the disease responds in the first weeks of treatment.

Situation Typical outcome
Single-system LCH Survival close to 100%; single lesions often heal completely
Multisystem LCH without risk organs Survival close to 100%; reactivation in about 30%
Multisystem LCH with risk organs Survival now about 85-95% with modern treatment; poorer if the disease does not respond within 6 weeks
Pulmonary LCH in adults Often stabilises after stopping smoking; a minority develop progressive lung damage

Reactivation means the disease comes back after it has settled. It usually happens within the first 2 years, often in the bones, skin or ears, and is generally treatable.

Long-term effects

About half of people with multisystem LCH have at least one long-term effect, so follow-up continues for many years.

Long-term effect Details
Diabetes insipidus Up to 25% of children with multisystem disease; usually permanent
Other hormone problems Growth hormone deficiency, delayed puberty, thyroid problems
Bone and teeth Changes in face shape, uneven growth, tooth loss
Hearing loss After ear involvement
Neurodegenerative LCH A slow loss of balance, coordination and thinking skills, appearing years later; regular brain MRI and neurological checks help detect it early
Lung damage Reduced lung function, especially in smokers
Other cancers A slightly higher risk of some blood cancers and solid tumours

9. Living with LCH

  • Children usually continue school during treatment, with extra support during periods of low blood counts.
  • Keep all follow-up appointments, including growth checks, hormone tests, hearing tests and, where advised, brain MRI.
  • Learn the warning signs of diabetes insipidus, and contact the team quickly if thirst or urination increases.
  • Adults with lung involvement must stop smoking, including cannabis and e-cigarettes. Support from a stop-smoking service greatly improves the chances of success.
  • Protect the bones by avoiding contact sports while bone lesions are healing, if your team advises.
  • Patient groups such as the Histiocytosis Association and Histio UK offer information, family days and support.

10. Frequently asked questions

Question Answer
Is LCH a cancer? It is now classed as a neoplasm of myeloid cells and is treated by cancer specialists, but it behaves differently from most cancers and many forms are mild
Is it contagious or inherited? No. It cannot be caught and is almost never passed on in families
Will my child need chemotherapy? Not always. A single bone or skin lesion may need only a biopsy or observation
Can it come back? Yes, in about 1 in 3 people with multisystem disease. Reactivations are usually milder and treatable
Will my child grow normally? Most do. Growth and puberty are checked regularly, and hormone treatment is given if needed

Resources

  1. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  2. Emile, J.F. et al. (2016) ‘Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages’, Blood, 127(22), pp. 2672-2681.
  3. Allen, C.E., Merad, M. and McClain, K.L. (2018) ‘Langerhans-cell histiocytosis’, New England Journal of Medicine, 379(9), pp. 856-868.
  4. Rodriguez-Galindo, C. and Allen, C.E. (2020) ‘Langerhans cell histiocytosis’, Blood, 135(16), pp. 1319-1331.
  5. Badalian-Very, G. et al. (2010) ‘Recurrent BRAF mutations in Langerhans cell histiocytosis’, Blood, 116(11), pp. 1919-1923.
  6. Haupt, R. et al. (2013) ‘Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years’, Pediatric Blood & Cancer, 60(2), pp. 175-184.
  7. Gadner, H. et al. (2013) ‘Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis’, Blood, 121(25), pp. 5006-5014.
  8. Goyal, G. et al. (2022) ‘International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults’, Blood, 139(17), pp. 2601-2621.
  9. Donadieu, J. et al. (2019) ‘Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study’, Journal of Clinical Oncology, 37(31), pp. 2857-2865.
  10. Diamond, E.L. et al. (2019) ‘Efficacy of MEK inhibition in patients with histiocytic neoplasms’, Nature, 567(7749), pp. 521-524.
  11. National Cancer Institute (2026) Langerhans Cell Histiocytosis Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/langerhans/patient/langerhans-treatment-pdq (Accessed: October 2026).
  12. Histiocytosis Association (2026) Langerhans cell histiocytosis. Available at: https://histio.org/ (Accessed: October 2026).

Prepared by the editorial team, October 2026.